Overview

Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BIA 9-1067

Status:
Completed
Trial end date:
2017-04-27
Target enrollment:
Participant gender:
Summary
The purpose is to and to assess the mass balance recovery after a single oral dose of [14C]-BIA 9-1067 and to provide plasma, urine and faecal samples for metabolite profiling and structural identification.
Phase:
Phase 1
Details
Lead Sponsor:
Bial - Portela C S.A.
Treatments:
Opicapone